Oct. 23 at 7:17 PM
Medpace’s Strong Quarter Signals Biotech Recovery
Medpace Holdings reported third-quarter new orders of
$789 million, up 49% year-over-year, with revenue of
$659.9 million and earnings of
$3.86 per share—well above forecasts. The results indicate renewed momentum in biotech after years of slowdown.
The company’s backlog grew 2.5% from 2024 levels, suggesting improving conditions for small and midsize biotech firms. Shares jumped over 10% Thursday following a premarket surge of more than 17%.
The SPDR S&P Biotech ETF has risen 20% since September, far outpacing the S&P 500’s 4% gain. Sector optimism has been fueled by M&A activity and easing policy concerns, including President Trump’s recent drug pricing deal with Pfizer.
Analysts say Medpace’s strong bookings and improved funding conditions for clients show the biotech recovery is gaining traction.
$MEDP $XBI $SPX $PFE $ICLR